Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyOscar Health biomarker testing Coverage & Prior Au…
    Ask Trek AI about this page
    CurrentOscar HealthPolicy N/A

    Biomarker Testing for Autoimmune Rheumatic Disease

    Customize your policy alerts

    Sign up for all Oscar Health policy alerts

    Know when Oscar Health releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines coverage and limits for serologic biomarker testing (ANA, ENA, RF, anti-CCP, anti-dsDNA, select disease-specific antibodies and biomarker panels) used in evaluation and monitoring of systemic autoimmune rheumatic diseases for Oscar Health members.

    Policy Summary
    PayerOscar Health
    PolicyBiomarker Testing for Autoimmune Rheumatic Disease
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage changes
    Effective DateOct 1, 2026
    Last ReviewJun 16, 2026
    Next Review DateJun 16, 2026
    Key ActionSubmit clinical documentation showing signs/symptoms and positive ANA or other diagnostic criteria when requesting testing; prior authorization may be required for proprietary multianalyte tests.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    OnceANA allowed during initial workup
    Up to 2Additional ANA tests per lifetime
    ≤4/yrdsDNA testing frequency
    Not allowedANA/ENA in asymptomatic individuals

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Not allowedProprietary multianalyte panels for SLE/CTD
    2026-10-01Policy effective date

    Coverage Criteria — When Testing Is Medically Necessary

    inv-01: Medically necessary testing — Covered when specific clinical conditions are met as follows:

    Covered when ALL of the following clinical conditions are met:

    ANA screening for symptomatic individuals: For individuals with signs or symptoms of an autoimmune disease, screening for disease using antinuclear antibodies (ANA) meets criteria: once during initial workup and up to two additional tests per lifetime if new or more severe signs or symptoms develop.once; up to 2 additional per lifetime
    ENA panel following abnormal ANA: For individuals with an abnormal, raised ANA titer and clinical correlation with the appropriate autoimmune disorder, extractable nuclear antigens (ENA) panel testing of specific autoantibodies meets criteria.
    RF and/or anti-CCP for suspected RA: For individuals with painful and swollen joints suggestive of rheumatoid arthritis (RA), testing for rheumatoid factor (RF) and/or anti-CCP antibodies meets criteria: once during initial workup; if initial testing did not result in diagnosis, up to two additional tests per lifetime if symptoms persist or additional symptoms develop.once; up to 2 additional per lifetime if needed
    Anti-dsDNA monitoring in diagnosed SARD: For individuals with an initial positive ANA test and a diagnosis of systemic autoimmune rheumatic disease, testing of anti-double-stranded DNA (anti-dsDNA) up to four (4) times per year meets criteria.<=4 per year
    Condition-specific antibody testing with negative/low-positive ANA: For individuals with a negative or low positive ANA test, the following condition-specific antibody testing meets criteria: testing for anti-Jo-1 in a unique clinical subset of myositis; testing for anti-SSA in the setting of lupus or Sjögren's syndrome.

    inv-02: Not medically necessary / Not covered testing — The following do not meet criteria:

    The following do not meet criteria (any of the following may be considered not medically necessary):

    Monitoring with ANA: Monitoring of disease with ANA testing or ANA titers does not meet criteria.
    Screening asymptomatic individuals: For individuals without symptoms suggestive of an autoimmune disorder, ANA and/or ENA testing does not meet criteria.
    Specific antibodies without positive ANA: Testing of specific antibodies in the absence of a positive ANA test does not meet criteria except where specified in the medically necessary criteria (e.g., anti-Jo-1, anti-SSA as noted).
    Wellness/exam testing: For asymptomatic individuals, testing of ANA and/or ENA during a wellness visit or general exam without abnormal findings does not meet criteria.

    inv-03: Reflex testing recommendations — Guidance and evidence summaries for test use

    Guidance and evidence-based reflex testing recommendations to guide appropriate downstream testing:

    Reflex testing after positive ANA: When ANA IIF screening is positive (pattern-specific findings and typical titres ≥1:160), reflex testing for anti-dsDNA and ENA sub-specificities is indicated; selection of reflex tests should be guided by the HEp-2 pattern (examples: homogeneous → anti-dsDNA/ENA; centromere → CENP-B confirmation only if low titre or unclear pattern).titre >=1:160 for reflex decisions as referenced in Table 1

    inv-04: Analytical validity and assay choice — Selection of initial ANA assay

    Considerations for selection of the initial ANA assay and follow-up testing:

    Initial assay selection and follow-up: Indirect immunofluorescence (IIF) on HEp-2 cells remains the gold standard because it presents a broad spectrum of antigens; solid‑phase assays (ELISA, FEIA, CIA, multiplex) offer higher throughput and less subjectivity but have limited antigen panels. If a solid‑phase assay is negative and clinical suspicion for a systemic autoimmune rheumatic disease remains strong, perform IIF.

    inv-05: Proprietary test evidence — Proprietary multianalyte and molecular tests

    Summary of proprietary multianalyte and molecular test claims and observed clinical findings reported in the literature:

    AVISE / MAP clinical observations: AVISE Lupus and related MAP/CB-CAP panels combine cell-bound complement activation products with autoantibodies and report a composite index; studies report that positive MAP results are associated with higher rates of SLE diagnosis, may influence treatment decisions, and in some cohorts predict progression from probable to classifiable SLE (e.g., MAP >0.8 predicting transition to classifiable SLE).
    PrismRA (MSRC) claims: PrismRA (molecular signature response classifier) is reported to predict TNF‑inhibitor non-response and to influence treatment selection decisions; validation cohorts report predictive performance (examples: PPV 89.7%, specificity 86.8%, sensitivity 50%) and associations with odds of inadequate ACR50 response.

    inv-06: Evidence summaries for multi-biomarker tests — Reported performance characteristics and literature evidence

    Reported performance characteristics, study findings, and limitations from the evidence base for multi‑biomarker tests:

    MAP performance and outcomes: MAP (multi‑analyte profile) has been reported in modeling and cohort studies to yield sensitivity ~80% and specificity ~86% versus standard diagnostic laboratory testing; MAP was associated with higher positive predictive value and modeled cost savings in one analysis.
    PrismRA / MSRC validation data: PrismRA validation in CERTAIN and NETWORK‑004 cohorts reported specificity 86.8%, sensitivity 50%, and PPV 89.7%; a non‑response MSRC prediction was associated with an increased odds ratio (≈4.1) for inadequate ACR50 response.
    MBDA (Vectra DA) evidence and limits: MBDA (Vectra DA) uses 12 serum proteins to generate a disease activity score (low ≤29; moderate 29–44; high >44) and correlates with DAS28‑CRP (r≈0.72); MBDA results have influenced treatment decisions in observational studies but randomized trial data show limited responsiveness for some interventions, and consistent clinical outcome benefit has not been established.

    inv-07: SLICC criteria (SLE) — Classification items used in clinical/immunologic classification

    SLICC classification items used in clinical and immunologic assessment of suspected SLE:

    SLICC Clinical Criteria: Acute cutaneous lupus (eg malar/subacute), chronic cutaneous lupus (eg discoid), nonscarring alopecia, oral or nasal ulcers, joint disease, serositis, renal criteria (eg urine protein‑to‑creatinine ratio ≈500 mg protein/24 hours or RBC casts), neurologic criteria (eg seizures, psychosis, myelitis), hemolytic anemia, leukopenia/lymphopenia, and thrombocytopenia.
    SLICC Immunologic Criteria: Immunologic items include ANA, anti‑dsDNA, anti‑Sm, antiphospholipid antibodies, low complement (low C3, low C4, or low CH50), and direct Coombs test in the absence of hemolytic anemia.

    inv-08: RA diagnostic and monitoring guidance — Guideline-based recommendations relevant to RA diagnosis and testing:

    Guideline-based recommendations relevant to RA diagnosis and testing (selection and monitoring):

    Inflammatory marker testing: CRP or ESR is recommended as preferred tests to indicate inflammatory activity; CRP is more sensitive to short‑term fluctuations while ESR may be elevated in many but not all with active inflammation.
    Rheumatoid factor (RF): Offer RF testing in people with suspected RA who have synovitis; RF has limited sensitivity and specificity and seropositive RA typically portends worse prognosis.
    Anti‑CCP testing: Consider anti‑CCP measurement when RF is negative and combination therapy is being considered, as anti‑CCP may add diagnostic value.
    Referral for specialist: Refer patients with suspected persistent synovitis of undetermined cause to a specialist; urgent referral is recommended when small joints are affected, more than one joint is involved, or symptom duration exceeds three months.

    Serum biomarker panel testing that reports proprietary algorithms or index scores to diagnose, prognose, or monitor systemic lupus erythematosus (SLE) or other connective tissue diseases (CTDs) is not supported by sufficient published evidence. Examples cited in the policy include AVISE CTD, AVISE SLE Monitor, AVISE SLE Prognostic, aisle® DX Disease Activity Index, Early Sjögren's Syndrome Profile, and tissue‑specific marker panels; such tests DO NOT MEET CRITERIA for routine coverage. This determination reflects the policy's conclusion that available literature does not confirm these panels are required and beneficial for patient diagnosis or management.

    Providers should rely on established serologic tests (ANA screening, ENA sub‑specificities, anti‑dsDNA, RF, anti‑CCP) and documented clinical correlation when evaluating suspected SLE/CTD rather than ordering proprietary multi‑analyte panels as a first‑line diagnostic or monitoring strategy.

    Repeat antinuclear antibody (ANA) testing after an initially negative ANA has limited clinical utility and high cost. A cited study found that among patients who repeated ANA testing after a negative result, only a small proportion converted to positive and such conversions did not change diagnosis; the authors concluded that ‘repeat ANA testing after a negative result has low utility.’ The policy therefore discourages routine repeat ANA assays without a new or worsening clinical indication.

    If new or more severe signs or symptoms of autoimmune disease develop, the policy permits repeat ANA testing per the specified coverage thresholds (see medically necessary testing criteria); absent new clinical indications, repeat testing following a negative ANA is unlikely to be medically necessary.

    Clinical guidelines and Choosing Wisely recommendations advise against ordering ANA subserologies or broad autoantibody panels in the absence of a positive ANA and compatible clinical suspicion. The policy echoes this guidance: do not order ENA/subserology panels without a positive ANA and documented clinical signs of immune‑mediated disease, and payers may require documentation of a positive ANA and supporting clinical findings before authorizing reflex or panel testing.

    When ANA screening is positive, reflex testing for specific ENA antibodies and anti‑dsDNA—guided by HEp‑2 pattern and titer—may be indicated and should be selected based on clinical context and established reflex algorithms.

    If this policy conflicts with any applicable government coverage directive (for example, a Medicare National Coverage Determination or Local Coverage Determination, or a state Medicaid policy), the applicable government policy will take precedence and will be used to make coverage determinations. Providers and reviewers should consult the current Medicare Coverage Database or the relevant state Medicaid resources for up‑to‑date government guidance when making determinations.

    This section cites evidence‑based scientific references supporting the policy’s clinical summaries and rationale. Representative references include peer‑reviewed evaluations of ANA assay methods and studies of multianalyte panels and MBDA/PrismRA validation and utility (for example, Alsaed et al. 2021; Wallace et al. 2019; Clarke et al. 2020; Mellors et al. 2020). These references are provided to inform medical necessity review and clinical interpretation of test performance and limitations.

    The bibliography entries listed in chunks 72–79 supply the underlying literature referenced elsewhere in the policy; this section does not itself state coverage exclusions but serves as the supporting evidence base for the policy statements.

    The policy identifies several specific uses that are discouraged: ANA or ENA testing in asymptomatic individuals (including during routine wellness visits), use of ANA titers for routine monitoring of disease activity, and ordering specific autoantibody tests or broad autoantibody panels without a positive ANA and compatible clinical findings. These practices DO NOT MEET CRITERIA and may be subject to denial if submitted without appropriate documentation of signs or symptoms.

    Guideline recommendations cited (ACR / Choosing Wisely) state: “Do not test antinuclear antibody (ANA) subserologies without a positive ANA and clinical suspicion of immune‑mediated disease.”

    Routine repeat ANA testing after an initial negative result generally lacks clinical utility and is unlikely to change diagnosis when performed without new clinical findings. A large observational analysis concluded that repeat negative→positive conversions were uncommon and did not alter diagnosis, leading the authors to state that ‘repeat ANA testing after a negative result has low utility’. Accordingly, repeat ANA testing without new or evolving signs or symptoms may be considered not medically necessary.

    Per the policy, repeat ANA testing is permitted only when clinically justified (for example, when new or more severe symptoms arise), consistent with the specified coverage thresholds for additional testing.

    Current RA management guidelines and task‑force reports do not recommend routine use of multi‑biomarker panels (for example, MBDA/Vectra DA or PrismRA) for diagnosis or routine disease‑management decisions. The 2021 ACR guidance and subsequent international task force documents reviewed in the policy do not endorse these proprietary multi‑biomarker tests as standard diagnostic or monitoring tools for RA.

    Additionally, randomized trial data have raised concerns about responsiveness of some multi‑biomarker scores (for example, MBDA changes below the minimally important difference in a randomized RA trial), and the policy therefore does not support routine clinical use of these tests for RA diagnosis or management absent stronger evidence.

    Some chunks of the evidence section compile citations and reference listings without making explicit 'not medically necessary' determinations themselves. These bibliographic entries support the policy’s clinical conclusions elsewhere in the document but do not by themselves state coverage exclusions or determinations.

    Reviewers should rely on the policy’s coverage and not‑medically‑necessary sections for coverage stance; the cited literature is provided to substantiate those policy decisions.

    Procedure and Proprietary Codes

    Applicable CPT CodesCPT
    86038Antinuclear antibodies (ANA).
    86039Antinuclear antibodies (ANA); titer.
    86200Cyclic citrullinated peptide (CCP), antibody.
    86225Deoxyribonucleic acid (DNA) antibody; native or double stranded.
    86235Extractable nuclear antigen, antibody to, any method (eg, nRNP, SS-A, SS-B, Sm, RNP, Sc170, J01), each antibody.
    86430Rheumatoid factor; qualitative.
    86431Rheumatoid factor; quantitative.
    Proprietary/PLA CodesHCPCS
    0039ULab/Manufacturer: University of Washington/Bio-Rad. Autoimmune (systemic lupus erythematosus), IgG and IgM analysis of 80 biomarkers, algorithm reported with a risk score (Proprietary test: SLE-key® Rule Out).

    Provider Actions, Prior Authorization & Documentation

    Prior Authorization

    Prior authorization when medical necessity review applies

    Prior authorization is required when services are subject to medical necessity review per member benefits and authorization guidelines; this policy is used to guide medical necessity determinations for ANA/ENA, RF/anti-CCP, anti-dsDNA and select antibodies.

    • Authorization requirement depends on member benefit and payer-specific procedures.
    • Services must meet medical necessity and coding/billing guidelines at time of request.
    Prior Authorization

    Prior authorization may be required for proprietary/multianalyte tests

    Proprietary multianalyte/molecular signature tests (examples: AVISE Lupus/CTD, PrismRA, Vectra DA, aiSLE DX) are discussed as diagnostic/prognostic/monitoring tools and may require prior authorization where payer rules restrict coverage of LDTs or proprietary panels.

    • AVISE tests use a two‑tiered method and CB‑CAPs; AVISE Lupus is described as “an ideal test for ANA positive patients with a clinical suspicion of lupus.”

    Background and Scope

    Systemic autoimmune rheumatic diseases (SARDs) represent a heterogeneous group that includes systemic lupus erythematosus (SLE), Sjögren's syndrome, mixed connective tissue disease, systemic sclerosis, idiopathic inflammatory myopathies, and rheumatoid arthritis. These disorders are characterized by autoantibodies and immune‑mediated tissue injury, and serologic testing (ANA by IIF on HEp‑2 cells, ENA sub‑specificities, anti‑dsDNA, RF, anti‑CCP, and selected disease‑specific antibodies) is commonly used in evaluation and classification.

    The policy emphasizes that ANA by indirect immunofluorescence remains the reference screening test with high sensitivity but limited specificity, and that disease‑specific antibodies or targeted reflex testing should be performed only with appropriate clinical correlation. Proprietary multianalyte panels and other multi‑biomarker assays lack sufficient published evidence to support routine diagnostic, prognostic, or monitoring use across SARDs, which underpins the policy’s restrictive coverage stance for such panels.

    Definitions and Test Descriptions

    Antinuclear antibody (ANA)
    DefinitionAntinuclear antibody (ANA): autoantibodies that bind nuclear constituents; listed in the terminology table as 'ANA' and used to screen for systemic autoimmune rheumatic diseases.
    Role in evaluationANA by IIF on HEp-2 cells is the reference screening test with high sensitivity for SARDs (eg, >95% in SLE) but limited specificity and low positive predictive value when isolated in healthy individuals.
    LimitationsIIF is labor-intensive, requires trained interpretation for titer and pattern, and often necessitates reflex testing because staining patterns do not reliably identify the specific autoantibody.
    Frequency in diseasesReported ANA frequency: SLE and SSc 95–100%; Sjögren's 50–70%; RA 30–50%.
    Anti-CCP (Anti-cyclic citrullinated peptide antibodies)
    Definition
    Policy Summary
    PayerOscar Health
    PolicyBiomarker Testing for Autoimmune Rheumatic Disease
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage changes
    Effective DateOct 1, 2026
    Last ReviewJun 16, 2026
    Next Review DateJun 16, 2026
    Key ActionSubmit clinical documentation showing signs/symptoms and positive ANA or other diagnostic criteria when requesting testing; prior authorization may be required for proprietary multianalyte tests.
    SourceLink
    On This Page
    Coverage Criteria — When Testing Is Medically NecessaryProcedure and Proprietary CodesProvider Actions, Prior Authorization & DocumentationBackground and ScopeDefinitions and Test Descriptions
    Unproven biomarker panels for SLE/CTD: Serum biomarker panel testing (with or without proprietary algorithms/index scores) designed to diagnose, prognose, or monitor SLE or connective tissue diseases (examples: AVISE CTD, AVISE SLE Monitor, AVISE SLE Prognostic, aisle® DX Disease Activity Index, Early Sjögren's Syndrome Profile, Tissue Specific Markers for Early Diagnosis of Sjögren's Disease) does not meet criteria due to insufficient published evidence.
    Other serum biomarker panels for RA diagnosis: For the diagnosis of RA, testing for serum biomarkers not discussed above, alone or in a panel (e.g., Seronegative Rheumatoid Arthritis Profile), does not meet criteria.
  1. PrismRA (MSRC) predicts TNFi non‑response using a 23‑feature RNA signature.
  2. Vectra DA and aiSLE DX are listed as proprietary MBDA/DA tests.
  3. Prior Authorization

    ANA screen required before subserologies/panels

    Do not order ANA subserologies or broad autoantibody panels without a positive ANA screen and clinical suspicion; payers may require documentation of a positive ANA and clinical indication prior to authorizing reflex or panel testing.

    • ACR/Choosing Wisely recommendation: “Do not test antinuclear antibody (ANA) subserologies without a positive ANA and clinical suspicion of immune‑mediated disease.”
    • Policy states ENA panel testing meets criteria only for individuals with an abnormal, raised ANA titer and clinical correlation.
    Billing Rule

    Procedure codes listed — include when requesting authorization/billing

    Reportable CPT/PLA codes for ANA/ENA/RF/anti‑CCP/anti‑dsDNA and listed proprietary tests are included in the policy and may be used when requesting authorization or submitting claims; follow payer-specific prior‑auth procedures.

    • Listed CPTs include 86038, 86039, 86200, 86225, 86235, 86430, 86431.
    • Proprietary PLA code 0039U and several vendor tests (aisle® DX, SLE‑key®, Seronegative RA Panel) are listed in VIII. Applicable CPT/HCPCS Procedure Codes.
    Note

    No universal prior‑auth workflow specified in policy text

    No additional payer‑level prior authorization rules are specified within these chunks; authorization practice remains dependent on member benefits and payer procedures.

    • Publication history and policy applicability are provided, but no explicit universal prior‑auth workflow is defined in the cited sections.
    Step Therapy

    Drug step therapy context — no test‑based mandates specified

    csDMARDs are first‑line for RA and bDMARDs (including TNFis) are used when csDMARDs fail; the policy does not establish drug step‑therapy mandates for these agents.

    • Background notes describe standard csDMARD → bDMARD sequencing but do not impose test‑based step therapy requirements.
    Note

    PrismRA may inform biologic selection but does not mandate step therapy

    PrismRA predicts TNF‑inhibitor non‑response and could be used to inform biologic selection prior to initiating TNFi therapy; implementation may interact with but does not create an explicit payer step‑therapy requirement.

    • PrismRA uses a 23‑feature MSRC integrating RNA sequencing and clinical features to predict TNFi non‑response.
    • CERTAIN and NETWORK‑004 validations report PPV 89.7%, specificity 86.8%, sensitivity 50%.
    Step Therapy

    No explicit step‑therapy mandates for MBDA/PrismRA in guidelines

    Clinical RA management guidelines and the policy text do not specify step‑therapy requirements for MBDA (Vectra DA) or PrismRA; no explicit testing‑based step therapy is recommended.

    • 2021 ACR RA guideline and other task forces do not recommend routine use of multi‑biomarker tests for diagnosis or management.
    • Policy statements note absence of explicit step‑therapy testing rules in the guideline extracts.
    Step Therapy

    Testing sequencing in RA workup (NICE guidance)

    NICE guidance implies sequencing in RA workup: refer patients with suspected persistent synovitis to specialists and test RF; consider anti‑CCP when RF is negative and combination therapy is considered.

    • NICE: “Offer to test for rheumatoid factor in people with suspected rheumatoid arthritis who have synovitis.”
    • “Consider measuring anti‑CCP… if they are negative for RF and combination therapy is being considered.”
    Note

    No step‑therapy rules provided in cited studies

    No formal step‑therapy rules are specified in the cited literature; studies cited describe evaluation and validation of multibiomarker panels and MAP tests but do not define payer step therapy.

    • Evidence references and clinical validation studies for MAP/MBDA/PrismRA are listed, but no step‑therapy policies are provided.
    Documentation Required

    Required documentation with clinical signs/symptoms and benefit verification

    Providers must submit clinical documentation demonstrating signs/symptoms, clinical correlation, and benefit coverage at time of request; insufficient documentation may result in denial.

    • Documentation should show active signs/symptoms consistent with the requested test and member benefit eligibility at time of request.
    • Coding should follow standard industry coding/billing guidelines to avoid claim denial.
    Documentation Required

    If ANA positive — perform reflex anti‑dsDNA/ENA guided by HEp‑2 pattern/titre

    If an ANA screen is positive, reflex testing for anti‑dsDNA and ENA sub‑specificities is recommended and the reflex choices should be guided by HEp‑2 IIF pattern and titre (see Table 1 for pattern→reflex mappings).

    • Table 1: for nuclear homogeneous ≥1:160 reflex = anti‑dsDNA and ENA; centromere pattern requires anti‑CENP‑B only in dubious/low titre cases.
    • Reflex testing aims to identify sub‑specificities tied to distinct ANA patterns.
    Documentation Required

    Document classification criteria entry status and relevant clinical findings

    Document presence or absence of classification entry and clinical criteria (for example ANA at HEp‑2 titer ≥1:80 per EULAR/ACR and SLICC clinical/immunologic items) when ordering or interpreting SLE‑related biomarker testing.

    • EULAR/ACR: ANA at titer ≥1:80 on HEp‑2 cells is an entry criterion for SLE.
    • SLICC criteria list required clinical and immunologic items (including ANA, anti‑dsDNA, anti‑Sm, low complement) that should be documented.
    Documentation Required

    Include SLICC‑consistent clinical justification and evidence references

    When ordering lupus‑related testing, include clinical justification aligned with SLICC/ACR/EULAR criteria (list clinical and immunologic SLICC items) and cite supporting scientific evidence when available.

    • Policy requires clinical criteria consistent with SLICC when testing for lupus and recommends including relevant diagnostic rationale with CPT/proprietary test requests.
    • Evidence references (chunks 72–74) are provided to support medical necessity documentation.
    Denial Risk

    Denial risk: testing without symptoms or for proprietary panels

    Claims for ANA/ENA testing without signs/symptoms of autoimmune disease, ANA/ENA ordered during wellness visits in asymptomatic individuals, and proprietary multianalyte panel testing for SLE/CTD risk denial.

    • Policy explicitly states ANA/ENA testing in asymptomatic individuals and testing during wellness exams does not meet criteria.
    • Serum biomarker panels with proprietary algorithms (eg, AVISE CTD, AVISE SLE Monitor, aisle® DX) do not meet criteria due to insufficient evidence.
    Denial Risk

    Denial risk: repeat ANA after negative result without new indication

    Repeat ANA testing after an initial negative ANA has low utility and may be denied without a new clinical indication — repeat testing showed low yield and increased cost in cited studies.

    • Yeo et al. (2020) found only 19% of repeated ANA tests after a prior negative converted to positive and did not change diagnosis; policy notes repeats lack utility.
    • Policy allows up to two additional ANA/RF tests per lifetime only if new or more severe signs/symptoms develop.
    Denial Risk

    Denial risk: ANA subserologies without a positive ANA

    Ordering ANA subserologies or autoantibody panels without a positive ANA and clinical suspicion is discouraged and may be questioned by guideline‑based review and payer authorization.

    • ACR/Choosing Wisely: “Do not test antinuclear antibody (ANA) subserologies without a positive ANA and clinical suspicion.”
    • Policy states specific antibody testing outside a positive ANA generally does not meet criteria.
    Denial Risk

    Government policy precedence may affect authorization/denial

    Coverage determinations will defer to applicable government policies (LCDs/NCDs); if governmental policy conflicts with this policy, the government policy will control and may affect authorization/denial.

    • Policy instructs to consult Medicare/Medicaid coverage databases for the most up‑to‑date government policies.
    • Providers should verify state Medicaid or LCD/NCD provisions that may supersede this policy.
    Note
    Note
    Anti-cyclic citrullinated peptide antibodies (anti-CCP): autoantibodies directed against citrullinated peptides, listed in terminology as Anti-CCP.
    Clinical useUsed in the diagnostic workup of suspected rheumatoid arthritis and may add diagnostic value, particularly when rheumatoid factor (RF) is negative.
    Guideline contextNICE and other guideline bodies recommend considering anti-CCP when RF is negative and combination therapy is being considered.
    Anti-dsDNA (Anti-double-stranded DNA antibodies)
    DefinitionAnti-double-stranded DNA (anti-dsDNA): autoantibodies directed against native double-stranded DNA, listed in terminology as Anti-dsDNA.
    Clinical associationAnti-dsDNA antibodies are present in approximately two-thirds of patients with SLE and are associated with disease activity and lupus nephritis.
    Monitoring noteSerial monitoring of anti-dsDNA has modest correlation with disease activity; recommended following a positive ANA when SLE is suspected.
    ANA IIF — HEp-2 indirect immunofluorescence assay
    Assay descriptionANA IIF: indirect immunofluorescence assay on HEp-2 cells (IIF) using HEp-2 substrate; HEp-2 cells present most clinically relevant nuclear autoantigens, making them ideal for screening.
    PerformanceIIF on HEp-2 has high sensitivity for screening SARDs and is considered the reference screening method, but interpretation of titer and pattern is subjective.
    Operational considerationsDisadvantages include labor-intensiveness, training requirements, and subjectivity; automated image analysis can distinguish positive vs negative but cannot reliably assign specific patterns.
    CB-CAPs / MAP (Cell-bound complement activation products and multianalyte panels)
    DefinitionCB-CAPs (cell-bound complement activation products): complement split products such as EC4d (erythrocyte-bound C4d) and BC4d (B-lymphocyte-bound C4d) measured by quantitative flow cytometry.
    MAP incorporationMAP panels (multianalyte assay panels) combine CB-CAPs with serologic autoantibodies (eg, ANA, anti-dsDNA, ENA components) and proprietary algorithms (eg, AVISE) to improve diagnostic specificity for SLE.
    Analytical noteAnalytical validation data report stability and reproducibility (eg, intra/inter-day CVs in low-to-mid single-digit to low double-digit percent ranges) for EC4d and BC4d measurements.
    PrismRA (MSRC)
    DefinitionPrismRA (MSRC): a proprietary molecular signature response classifier (MSRC) developed to predict tumor necrosis factor inhibitor (TNFi) non-response in rheumatoid arthritis using baseline RNA sequencing and clinical features.
    Test featuresDescribed as a 23-feature blood-based molecular classifier integrating transcriptomic data and clinical assessments for TNFi response stratification.
    Clinical validationValidated in CERTAIN and NETWORK-004 cohorts with reported performance metrics (see PrismRA/MSRC block).
    MAP — Multi-analyte profile combining C4d products with serologic tests
    DefinitionMAP (multi-analyte profile): a panel combining complement C4d activation products (EC4d, BC4d) with standard serologic lupus tests (eg, ANA, anti-dsDNA, anti-Sm, ENA components) and an algorithm to improve SLE diagnostic performance.
    Reported performancePublished analyses report MAP sensitivity ~80% and specificity ~86% versus SDLTs (sensitivity 83%, specificity 76%), with improved positive predictive value in modeled cohorts.
    ExamplesCommercial implementations include AVISE Lupus/AVISE CTD, which use two-tiered algorithms incorporating CB-CAPs and autoantibodies.
    PrismRA / MSRC — molecular signature response classifier
    DefinitionPrismRA / MSRC: a molecular signature response classifier using baseline RNA sequencing and clinical assessments to predict inadequate response to TNF inhibitor therapy in RA patients.
    Validation resultsCERTAIN and NETWORK-004 validations report PrismRA MSRC metrics: specificity 86.8%, sensitivity 50%, positive predictive value 89.7%, and an odds ratio ~4.1 for inadequate ACR50 response among predicted non-responders.
    Clinical implicationPrismRA predictions were associated with lower likelihood of remission and may inform biologic selection prior to TNFi initiation, per decision-impact and modeling studies.
    MBDA / Vectra DA
    DefinitionMBDA / Vectra DA: multi-biomarker disease activity test for rheumatoid arthritis based on 12 serum proteins (eg, IL-6, TNFRI, VCAM-1, CRP, SAA, leptin) producing a composite score.
    Score interpretationScore thresholds: low ≤29, moderate 29–44, high >44 disease activity; intended to complement clinical joint assessment, not replace it.
    Validation and correlationMBDA correlates with DAS28-CRP (r=0.72) and has been shown in studies to predict radiographic progression and influence treatment decisions, though consistent clinical outcome benefit is not established.
    SLICC criteria (SLE)
    DefinitionSLICC criteria: Systemic Lupus International Collaborating Clinics classification criteria for SLE comprising clinical (eg, cutaneous, mucosal, joint, serositis, renal, neurologic, hematologic) and immunologic items.
    Immunologic itemsInclude ANA, anti-dsDNA, anti-Sm, antiphospholipid antibodies, low complement (C3, C4, or CH50), and direct Coombs test in absence of hemolytic anemia.
    Clinical itemsInclude acute and chronic cutaneous lupus, nonscarring alopecia, oral/nasal ulcers, joint disease, serositis, renal criteria (eg, urine protein-to-creatinine ≥500 mg/24 hr or RBC casts), neurologic criteria, and hematologic abnormalities.
    Anti-CCP / RF
    Anti-CCPAnti-cyclic citrullinated peptide (anti-CCP) antibodies: used in RA diagnosis and may be particularly useful when RF is negative.
    Rheumatoid factor (RF)RF has low sensitivity and specificity for RA; seropositive RA generally has worse prognosis than seronegative RA.
    Guideline recommendationsGuidelines (NICE, BC, RACGP) recommend RF testing in suspected RA with synovitis and consider anti-CCP if RF negative or when combination therapy is contemplated.
    MAP / MBDA (Referenced multianalyte and multi-biomarker panels)
    MAP / MBDA overviewMAP: multianalyte panels combining CB-CAPs (EC4d, BC4d) with standard serologies; MBDA: 12-biomarker algorithm (Vectra DA) for RA disease activity — both are proprietary multi-marker panels referenced in the policy.
    Reported metricsMAP reported sensitivity ~80% and specificity ~86%; MBDA correlates with DAS28-CRP (r=0.72) and uses score thresholds (≤29 low, 29–44 moderate, >44 high).
    Clinical utility statementPublished studies report MAP may improve diagnostic specificity for SLE and MBDA may influence treatment decisions, but overall clinical outcome benefit and routine guideline endorsement are limited.